AI Insight
Researchers at Wistar Institute have developed a novel DNA-delivered bispecific T cell engager (BTE) that shows effectiveness against ovarian cancer in preclinical models. This advancement is significant because while BTEs have demonstrated success in treating blood cancers, they have historically shown limited efficacy against solid tumors like ovarian cancer. The new approach represents a potential breakthrough in adapting this immunotherapy platform for solid tumor treatment.
Why it matters
This development could expand treatment options for ovarian cancer patients, a disease that often has limited therapeutic alternatives and poor prognosis. If successful in clinical trials, this technology could potentially be adapted for other solid tumor types where conventional BTEs have failed.
Understand the Science
Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in preclinical studies. It’s a major development for this type of immunotherapy, which has been used successfully against blood cancers but has so far been less effective in solid tumors.
Source: Scientists develop DNA-delivered immunotherapy that targets ovarian cancer more effectively